Roche Holding Ag Stock Earnings Reports

Roche reported strong 2025 results with group sales up 7% (Pharma +9%, Diagnostics +2% impacted by China pricing reform). Core operating profit rose 13% and core EPS increased 11% (taxes weighed on EPS momentum). Management reiterated 2026 guidance: mid-single-digit group sales growth and high single-digit core EPS growth, and indicated further dividend increases in CHF. The quarter featured extensive positive pipeline news: EU approval for Gazyva in lupus nephritis, US/EU subcutaneous approval for Lunsumio, US filing for giredestrant, and multiple positive Phase III readouts (including fenebrutinib in RMS and PPMS, Enspryng in MOG‑AD, lidERA giredestrant in adjuvant breast cancer, PiaSky in aHUS, and several Gazyva indications). Roche highlighted 10 NMEs moving into Phase III (a company record) and positioned giredestrant and fenebrutinib as potential next‑generation, best‑in‑class launches. Diagnostics faced a material headwind from China healthcare pricing reforms (c. CHF 579m impact in 2025) but excluding China Diagnostics grew ~7%; Roche launched multiple diagnostic products and announced the long-awaited AXELIOS Sequencing Solution (positioned as a >CHF1bn opportunity). Cash flow was lower (CHF 16.2bn) due to working capital and inventory build; net debt improved slightly. Management confirmed a contract with the U.S. government that includes an exemption from tariffs in exchange for Medicaid rebates, other policy commitments, and a US investment pledge of $50bn over five years. Key near-term catalysts for investors: persevERA (giredestrant first-line) readout, the remaining fenebrutinib RMS study (FENhance 1), multiple Phase II/III readouts across CVRM, oncology and immunology through 2026, and AXELIOS sequencing commercialization.